TBK1 Kinase Inhibitor Compounds Selective Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for inhibitors of the kinase activity of TBK1 and/or IKKε to treat cancers, inflammatory, and metabolic disorders that have an active TBK1 and/or IKKε pathway.
Innovation Solution
The development of compounds with specific chemical structures that inhibit the kinase activity of TBK1 and/or IKKε, including various substituents and functional groups, which can be used to modulate their activity in cancer, inflammation, and metabolic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TBK1 and IKKε kinase activity is inhibited to treat cancers and inflammatory disorders, then therapeutic efficacy is improved, but potential off-target effects and toxicity may increase
Solution Approach 1:
The patent employs selective inhibition by designing compounds that specifically target TBK1 and IKKε kinases while sparing other kinase families. This is achieved through optimized binding pocket interactions that exploit unique structural features of TBK1/IKKε, thereby improving therapeutic efficacy while minimizing off-target effects and toxicity associated with broad-spectrum kinase inhibition
Solution Approach 2:
The patent utilizes structure-activity relationship (SAR) optimization to fine-tune compound parameters including potency, selectivity, and pharmacokinetic properties. By systematically modifying chemical substituents and evaluating their impact on kinase inhibition specificity, the patent achieves optimal balance between therapeutic efficacy and safety profile
2Manufacturing precision
If complex chemical structures with multiple substituents are used to enhance kinase inhibition specificity, then selectivity is improved, but synthesis complexity and manufacturing difficulty increase
Solution Approach 1:
The patent divides the kinase inhibitor molecule into distinct functional modules including a core heterocyclic scaffold, substituent groups at specific positions, and linking moieties. This segmentation allows independent optimization of each module for binding specificity while facilitating modular synthesis approaches that simplify manufacturing compared to constructing the entire molecule in a single complex sequence
Solution Approach 2:
The patent employs a versatile core heterocyclic scaffold that can accommodate multiple different substituent patterns while maintaining binding to the TBK1/IKKε kinase domain. This universal scaffold approach enables synthesis of multiple analogs from common intermediates, reducing overall manufacturing complexity while achieving desired specificity through substituent variation
Data Source
AI summary
Compounds having the following formula (I) and methods of their use and preparation are disclosed: